genz-682452
Modify Date: 2025-08-27 13:04:47
genz-682452 structure
|
Common Name | genz-682452 | ||
|---|---|---|---|---|
| CAS Number | 1401090-53-6 | Molecular Weight | 389.487 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C20H24FN3O2S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of genz-682452Ibiglustat (Venglustat) is an inhibitor of glucosylceramide synthase extracted from patent WO 2015089067 A1, compound example 64. |
| Name | venglustat |
|---|---|
| Synonym | More Synonyms |
| Description | Ibiglustat (Venglustat) is an inhibitor of glucosylceramide synthase extracted from patent WO 2015089067 A1, compound example 64. |
|---|---|
| Related Catalog | |
| In Vivo | Ibiglustat is in phase II clinical trials for the treatment of Fabry's disease. Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations of the GLA gene that codes for α-galactosidase A, leads to dysfunction of many cell types and includes a systemic vasculopathy[2]. Substrate reduction therapy is an approach that reduces the synthesis of lipids reaching the lysosome through inhibition of glucosylceramide synthase (GCS)[1]. |
| References |
[1]. WO 2015089067 A1 [2]. Schiffmann R, et al. Fabry disease. Handb Clin Neurol. 2015;132:231-48. |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Molecular Formula | C20H24FN3O2S |
| Molecular Weight | 389.487 |
| Exact Mass | 389.157318 |
| LogP | 4.13 |
| Index of Refraction | 1.613 |
| Storage condition | 2-8℃ |
| (3S)-1-Azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]-2-propanyl}carbamate |
| Carbamic acid, N-[1-[2-(4-fluorophenyl)-4-thiazolyl]-1-methylethyl]-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester |
| MFCD28502073 |
| venglustat |
| Ibiglustat |
| genz-682452 |
| Ansofaxine Hydrochloride |